Q-omics provides the consensus-scored MCHR1 profile across patient tissues and cancer cell-line models. MCHR1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, MCHR1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, MCHR1 RNA expression shows 14,226 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight CESC, KIRC, and TGCT as cancer lineages where MCHR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MCHR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MCHR1 survival associations across molecular data types. MCHR1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MCHR1 RNA expression–survival associations across cancer types. High MCHR1 expression shows unfavorable associations in CESC, OV, MESO, HNSC, KICH and LUSC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify CESC as the clearest survival context for MCHR1 RNA expression.
This table summarizes MCHR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MCHR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MCHR1 shows lower tumor expression in UCEC and higher tumor expression in KIRC, LUAD, LUSC, LIHC and BRCA. The KIRC box plot shows higher MCHR1 RNA expression in tumor versus normal tissue (log2 FC = +3.050, t-test p < 0.001).
This table shows molecular features associated with MCHR1 in patient tissues and cancer cell lines. In patient samples, MCHR1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MCHR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
